Overall, our study provides compelling evidence that could explain the association of CYLD downregulation at least with a subset of poor-prognosis invasive breast cancers and identify valuable elements of a growth regulatory framework that can be exploited for therapeutic and diagnostic purposes. Here, CYLD is linked to invasive breast carcinoma.